American College of Emergency Physicians

Clinical Policies Committee Conference Call
October 21, 2020

MINUTES

Participants

Committee members participating in all or part of the call: Stephen J. Wolf, MD, FACEP, Chair; Richard Byyny, MD, MSc, FACEP, Methodologist; Deborah B. Diercks, MD, MSc, FACEP; Seth R. Gemme, MD, FACEP; Charles J. Gerardo, MD, MHS, FACEP; Steven A. Godwin, MD, FACEP; Sigrid A. Hahn, MD, MPH; Benjamin W. Hatten, MD, MPH, FACEP; Sean M. Hickey, MD, EMRA Representative; Jon Mark Hirshon, MD, PhD, MPH, FACEP, Board Liaison; Jason S. Haukoos, MD, MSc, FACEP, Methodologist; Bruce M. Lo, MD, MBA, RDMS, FACEP; Sharon E. Mace, MD, FACEP, FAAP; Susan B. Promes, MD, MBA, FACEP; Kaushal H. Shah, MD, FACEP; Richard D. Shih, MD, FACEP; Molly E. Thiessen, MD; Christian A. Tomaszewski, MD, MS, MBA, FACEP; Jonathan H. Valente, MD, FACEP; Stephen P. Wall, MD, MSc, MAEd, Methodologist; Justin Winger, RN, PhD, ENA Representative; Yanling Yu, PhD, Patient Representative.

Also present for all or part of the call: Mandie Mims, MLS, Staff Liaison; Travis Schulz, MLS, AHIP, Staff Liaison.

Agenda

1. Board comments on draft stroke critical questions
2. Board comments on draft airway critical questions
3. Strategic Review – Process Assessment

Major Points Discussed

1. Board comments on draft stroke critical questions

   Dr. Lo led the discussion of the Board comments on the draft stroke critical questions. Three Board members provided comments. Dr. Lo will prepare responses to the suggestions and/or questions from the Board members. The critical questions will now be prepared for the literature search.

2. Board comments on draft airway critical questions

   Dr. Hahn with the assistance of Dr. Godwin led the discussion of the Board comments on the draft airway critical questions. One Board member provided a comment. The response from the Committee will be shared with the Board. The critical questions will now be prepared for the literature search.

3. Strategic Review – Process Assessment

   Dr. Hatten led the discussion on proposed changes to the structure of the policy development processes. The Committee had several question about the proposed changes. Dr. Hatten will further refine the revision of the clinical policy development processes and bring them back to the Committee for further discussion.